Platelets subvert T cell immunity against cancer via GARP-TGFβ axis

See allHide authors and affiliations

Science Immunology  05 May 2017:
Vol. 2, Issue 11, eaai7911
DOI: 10.1126/sciimmunol.aai7911

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Cancer immunotherapy according to GARP

Cancer, like microbes, can adapt to a single therapy, making combination therapies the approach of choice. Complementary therapies that decrease immunosuppression may boost the efficacy of immunotherapies. Now, Rachidi et al. report that targeting platelets improves adoptive T cell therapy of multiple cancers in mice. They found that transforming growth factor β (TGFβ) from platelets decrease T cell function largely through the expression of the TGFβ-docking receptor glycoprotein A repetitions predominant (GARP). These data suggest that combining immunotherapy with platelet inhibitors may be a complementary approach to cancer therapy.